Nivolumab plus Cabozantinib Versus Sunitinib for First-line Treatment of Advanced Renal Cell Carcinoma: 3-year Follow-up from the Phase 3 CheckMate 9ER Trial : Episode 5

A Post-hoc Analysis of CheckMate 9ER Data and Study Conclusions

May 22, 2023

By Toni K. Choueiri, MD
Rohit Gosain, MD

Video

A brief overview of post-hoc data from the CheckMate 9ER trial examining baseline characteristics and time to subsequent therapy in patients who received at least two years of nivolumab treatment, followed by study conclusions.

EP: 1.Overview of ccRCC and Introduction to the CheckMate 9ER Trial

EP: 2.A Closer Look at Study Design and Patient Demographics from the CheckMate 9ER Trial

EP: 3.CheckMate 9ER: Progression-free Survival, Overall Survival, and Objective

EP: 4.Adverse Events Following Use of Nivolumab Plus Cabozantinib in Patients With Advanced ccRCC

Now Viewing

A Post-hoc Analysis of CheckMate 9ER Data and Study Conclusions

EP: 1.Overview of ccRCC and Introduction to the CheckMate 9ER Trial

EP: 2.A Closer Look at Study Design and Patient Demographics from the CheckMate 9ER Trial

EP: 3.CheckMate 9ER: Progression-free Survival, Overall Survival, and Objective

EP: 4.Adverse Events Following Use of Nivolumab Plus Cabozantinib in Patients With Advanced ccRCC

EP: 5.A Post-hoc Analysis of CheckMate 9ER Data and Study Conclusions

EP: 6.Clinical Insights Surrounding CheckMate 9ER Updates and Use of Nivolumab Plus Cabozantinib in ccRCC

EP: 7.Recap: Combination Therapy Shows Promise in Renal Cell Carcinoma